---
title: "002317.SZ (002317.SZ) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/002317.SZ/news.md"
symbol: "002317.SZ"
name: "002317.SZ"
parent: "https://longbridge.com/en/quote/002317.SZ.md"
datetime: "2026-03-10T19:23:50.678Z"
locales:
  - [en](https://longbridge.com/en/quote/002317.SZ/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/002317.SZ/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/002317.SZ/news.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/002317.SZ/news.md) | [繁體中文](https://longbridge.com/zh-HK/quote/002317.SZ/news.md)


# 002317.SZ (002317.SZ) — Related News

### [Turning losses into profits in one year, profits skyrocketing by 200%!](https://longbridge.com/en/news/275248585.md)
*2026-02-08T23:17:46.000Z*
> In early 2026, Guangdong ZHONGSHENGYAOYE announced two major pieces of news: first, it authorized the rights for its sel

### [Healthcare Industry Daily (02.08): New Developments in the Pharmaceutical Industry](https://longbridge.com/en/news/275234523.md)
*2026-02-08T19:16:16.000Z*
> INNOVENT BIO has reached a global strategic cooperation with Eli Lilly to advance the development of new drugs in the fi

### [ZHONGSHENGYAOYE: The innovative drug Anladvi project has obtained top-line analysis data results from two Phase III clinical trials](https://longbridge.com/en/news/275221750.md)
*2026-02-08T08:30:34.000Z*
> ZHONGSHENGYAOYE's subsidiary, Guangdong Zhongsheng Ruichuang Biotechnology Co., Ltd., recently announced the topline ana

### [Taiwan Stock Market Dynamics: Strong Demand for New Drug Development and Technology, Further Advancements in Finance and Infrastructure](https://longbridge.com/en/news/274941034.md)
*2026-02-05T08:40:05.000Z*
> Taiwan's stock market dynamics show strong demand for new drug development and technology. Quanta Computer has made prog

### [ZHONGSHENGYAOYE turns losses into profits, expecting a net profit attributable to the parent company of 260 million to 310 million yuan in 2025](https://longbridge.com/en/news/273775096.md)
*2026-01-27T02:24:48.000Z*
> ZHONGSHENGYAOYE expects a net profit attributable to the parent company of 260 million to 310 million yuan in 2025, turn

### [1 billion yuan authorized cooperation! This company’s weight loss innovative drug has entered Phase III clinical trials, and the newly approved indications have huge demand | Institutional Research](https://longbridge.com/en/news/273772528.md)
*2026-01-27T01:30:07.000Z*
> 1 billion yuan authorized cooperation! This company’s weight loss innovative drug has entered Phase III clinical trials,

### [ZHONGSHENGYAOYE: The clinical trial for the new indication of the RAY1225 injection of the holding subsidiary has been approved](https://longbridge.com/en/news/273517409.md)
*2026-01-23T12:49:25.000Z*
> On the evening of January 23rd, ZHONGSHENGYAOYE announced that its holding subsidiary, Guangdong Zhongsheng Ruichuang Bi

### [A cooperation authorization of 1 billion yuan has been reached, ZHONGSHENGYAOYE bets on a popular track](https://longbridge.com/en/news/272965744.md)
*2026-01-19T11:08:08.000Z*
> ZHONGSHENGYAOYE has reached a cooperation agreement worth 1 billion yuan with Qilu Pharmaceutical, authorizing Qilu Phar